Physic Ventures

Physic Ventures

Physic Ventures operates out of San Francisco with a tightly defined mandate: invest in the consumer science of health and sustainability. The firm runs concentrated early-stage portfolios, typically targeting companies that commercialize scientific research for individual impact — whether through direct-to-consumer diagnostics, sustainable nutrition, or health-connected fintech products. Its approach blends venture capital with a thematic research-first ethos, seeking founders who translate peer-reviewed science into scalable consumer businesses. The firm's investment activity spans digital health, food-tech, and health-adjacent financial technology. It focuses on Seed and Series A rounds, occasionally following into later growth rounds. Known portfolio companies include LumiHealth, a digital therapeutic platform bridging clinical care and patient monitoring, and Olly Nutrition, a wellness brand that scaled through retail before its acquisition by Unilever. Physic Ventures also participated in rounds for Habit, a personalized nutrition startup later acquired by Viome. The firm concentrates its deal flow in North America, with secondary exposure to European health-tech startups that have regulatory pathways into US markets. Physic Ventures runs a lean team, characteristic of thematic, conviction-led micro-VC firms, and has not publicly disclosed its total assets under management or precise headcount. The San Francisco headquarters positions the firm within the Bay Area's dense ecosystem of university spinouts and medical research commercialization, though it has not announced additional office locations. No publicly named adjacent vehicles or foundations are associated with the firm's core fund structure. In recent years, the firm has continued to back early-stage science-forward consumer brands, though specific fund closes remain undisclosed as of the most recent public record. What structures Physic Ventures differently from broad healthcare or food VCs is its requirement for a direct-to-consumer angle grounded in scientific rigor. It does not invest in enterprise SaaS alone, nor in biotech therapeutics requiring FDA clinical trials, but rather in companies that make validated health science accessible to individuals at scale. This consumer-science mandate creates a narrow aperture that demands both technical diligence and retail brand-building acumen — a combination not easily replicated by generalist early-stage investors.